<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956838</url>
  </required_header>
  <id_info>
    <org_study_id>NL44428.068.13/METC 13-2-025</org_study_id>
    <nct_id>NCT01956838</nct_id>
  </id_info>
  <brief_title>The Effect of Bitter, Umami and Sweet Tastants on Food Intake</brief_title>
  <official_title>The Effect of Bitter, Umami and Sweet Tastants on Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The appearance of tastants in the small intestine can result in the activation of&#xD;
      a negative feedback mechanism from different parts of the intestine to the stomach, the small&#xD;
      intestine and to the central nervous system. These processes inhibit food processing,&#xD;
      appetite sensations and food intake, and furthermore they increase feelings of satiety and&#xD;
      satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg&#xD;
      (bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of&#xD;
      these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in&#xD;
      total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides&#xD;
      CCK and GLP-1.&#xD;
&#xD;
      Study design: To assess the effect of intraduodenal infusion of single ingredients and a&#xD;
      combination of tastants (bitter, umami and sweet) on ad libitum food intake.&#xD;
&#xD;
      Secondary Objective(s):&#xD;
&#xD;
        1. To investigate the effect of intraduodenal delivery of a combination of tastants on&#xD;
           satiation.&#xD;
&#xD;
        2. To assess the effect of intraduodenal delivery of a combination of tastants on&#xD;
           gastrointestinal hormone release.&#xD;
&#xD;
        3. To assess the effects of the tastants quinine, rebaudioside A and monosodium glutamate&#xD;
           on the parameters as mentioned under the primary objective, and under secondary&#xD;
           objectives 1 and 2.&#xD;
&#xD;
        4. To compare the effects, as mentioned under the primary objective, and under secondary&#xD;
           objectives 1 and 2, of the combination of tastants to those of the three single tastants&#xD;
           quinine, rebaudioside A and monosodium glutamate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum meal intake</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in ad libitum meal intake (as measured during ad libitum pasta meal). At end of the testday</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiation</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in satiation (as measured by VAS) per time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormones</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measurements in plasma levels of the gut hormones CCK, GLP-1, insulin and glucose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Umami</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of umami</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sweet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of sweet tastant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bitter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of bitter tastant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of a combination of tastants (umami, bitter and sweet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intraduodenal infusion of placebo (tap water)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>umami</intervention_name>
    <description>intraduodenal infusion of umami tastant</description>
    <arm_group_label>Umami</arm_group_label>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>bitter</intervention_name>
    <description>intraduodenal infusion of bitter tastant</description>
    <arm_group_label>bitter</arm_group_label>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sweet</intervention_name>
    <description>intraduodenal infusion of sweet tastant</description>
    <arm_group_label>combination</arm_group_label>
    <arm_group_label>sweet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Based on medical history and previous examination, no gastrointestinal complaints can&#xD;
             be defined.&#xD;
&#xD;
          -  Age between 18 and 65 years. This study will include healthy adult subjects (male and&#xD;
             female). Women must be taking contraceptives.&#xD;
&#xD;
          -  BMI between 18 and 25 kg/m2)&#xD;
&#xD;
          -  Weight stable over at least the last 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,&#xD;
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat),&#xD;
             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,&#xD;
             neurological/psychiatric diseases, allergy, major surgery and/or laboratory&#xD;
             assessments which might limit participation in or completion of the study protocol.&#xD;
             The severity of the disease (major interference with the execution of the experiment&#xD;
             or potential influence on the study outcomes) will be decided by the principal&#xD;
             investigator.&#xD;
&#xD;
          -  Use of medication, including vitamin supplementation, except oral contraceptives,&#xD;
             within 14 days prior to testing&#xD;
&#xD;
          -  Administration of investigational drugs or participation in any scientific&#xD;
             intervention study which may interfere with this study (to be decided by the principle&#xD;
             investigator), in the 180 days prior to the study&#xD;
&#xD;
          -  Major abdominal surgery interfering with gastrointestinal function (uncomplicated&#xD;
             appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon&#xD;
             judgement of the principle investigator)&#xD;
&#xD;
          -  Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological&#xD;
             dynamic)&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt;20 alcoholic consumptions per week)&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Blood donation within 3 months before the study period&#xD;
&#xD;
          -  Self-admitted HIV-positive state&#xD;
&#xD;
          -  Weight &lt;60kg&#xD;
&#xD;
          -  Non-tasters of sweet, bitter or umami&#xD;
&#xD;
          -  Evidence of MSG-hypersensitivity or Chinese restaurant syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Masclee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food intake</keyword>
  <keyword>tastants</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

